Pill makesgals pick dad,not the cad Oct 8, 2009
Barr Laboratories / Getty Images file. Women's health videos. (MSNBC -- Health)
Women's health Oct 8, 2009
Barr Laboratories / Getty Images file. . (MSNBC -- Health)
Dr Reddys Lab embroiled in patent infringement row with AMRI Sep 16, 2009
The agreements allowed Sanofi to sublicense two Allegra patents to Teva Pharmaceuticals and Barr Laboratories in the United States. AMRI now gets royalties on the sale of generic Allegra products by Teva and Barr. (India Times)
Federal Circuit Hands Sanofi-Aventis Win in Fight Over Generic Cancer Drug Sep 12, 2009
The defendants were represented at the Federal Circuit by (for Sandoz Inc.); (for Mayne Pharma Ltd.); (for Teva Parenteral Medicines Inc. and Barr Laboratories Inc); and (for Fresenius Kabi Oncology PLC). This article first appeared on blog on AmericanLawyer. (Law.com)
Newsweek: The complicated history of Plan B Aug 27, 2009
Four years later, Barr Laboratories (the maker of Plan B, which has since changed its name to Teva Pharmaceuticals) submitted an application to switch Plan B from prescription to over-the-counter status. The FDA rejected the application, citing a lack of data on women under 16 (a move Trussell and other EC advocates viewed as political, since contraceptive access is a charged political topic). (MSNBC -- Health)
Need to know: Citigroup appointme... Mar 21, 2009
Shire: The pharmaceuticals group has filed a lawsuit against US-based Mylan for infringing a patent on its kidney drug Fosrenol, days after a similar lawsuit against Barr Laboratories. Cosalt: The marine safety equipment specialist said that overall trading to date is in line with its expectations and first-quarter revenue in its marine and offshore divisions rose more than 20 per cent.. (New York Post -- Business)
Shire sues Barr over generic Fosrenol plan Mar 17, 2009
filed a patent infringement lawsuit Monday against Barr Laboratories over Barr s request to sell a generic version of Shire s Fosrenol drugs for kidney disease. The lawsuit was filed in response to an abbreviated new drug application filed by Barr with the Food and Drug Administration. (Philadelphia Business Journal, PA)
